Abstract - Platform/Combination Therapy Selection in Multiple Sclerosis

Multiple Sclerosis is a chronic disease, and, while no cure exists, aggressive management can reduce the frequency of relapse and the progression to disability. Evidence-based selection of an initial therapeutic agent and appropriate use of additional agents can significantly improve patient outcomes. Join two MS experts as they discuss a rationale for the selection of platform and combination therapies for multiple sclerosis, including how to manage relapses and breakthrough disease.

Important Drug Alert: Voluntary suspension in the distribution and marketing of TysabriŽ (natalizumab). Physicians should suspend dosing of TYSABRI until further notification. For more information, click here.